Lexaria Bioscience (LEXXW) Competitors $0.30 -0.08 (-20.40%) As of 04/1/2025 02:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock LEXXW vs. ATNFW, LBPSW, AARD, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aardvark Therapeutics (AARD), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. 180 Life Sciences 4D pharma Aardvark Therapeutics Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Lexaria Bioscience (NASDAQ:LEXXW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, community ranking, earnings, analyst recommendations, dividends and valuation. Does the MarketBeat Community believe in LEXXW or ATNFW? Lexaria Bioscience and 180 Life Sciences both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformLexaria BioscienceN/AN/A180 Life SciencesN/AN/A Which has higher earnings and valuation, LEXXW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$496.92KN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Does the media favor LEXXW or ATNFW? In the previous week, Lexaria Bioscience had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Lexaria Bioscience and 0 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 1.89 beat Lexaria Bioscience's score of 0.44 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Lexaria Bioscience Neutral 180 Life Sciences Very Positive Is LEXXW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets Lexaria BioscienceN/A N/A N/A 180 Life Sciences N/A N/A N/A SummaryLexaria Bioscience beats 180 Life Sciences on 2 of the 3 factors compared between the two stocks. Remove Ads Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXXW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXXW vs. The Competition Export to ExcelMetricLexaria BioscienceBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$115.16M$5.54B$7.86BDividend YieldN/A3.69%5.35%4.06%P/E RatioN/A3.1523.4418.67Price / SalesN/A4,117.48367.8787.31Price / CashN/A13.0138.1634.64Price / BookN/A35.606.634.09Net IncomeN/A-$87.82M$3.20B$246.93M7 Day Performance-25.00%-4.37%-5.00%-3.16%1 Month Performance20.48%57.62%-1.57%-6.74%1 Year Performance-80.89%86.75%8.72%-0.49% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXWLexaria BioscienceN/A$0.30-20.4%N/A-81.6%$0.00$496,923.000.007Short Interest ↑Gap DownATNFW180 Life SciencesN/A$0.01+6.1%N/A-14.6%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAARDAardvark TherapeuticsN/A$9.24-6.8%$30.50+230.1%N/A$0.00N/A0.0018Analyst ForecastNews CoverageAEHAWAesther Healthcare AcquisitionN/A$0.02+0.5%N/A-83.3%$0.00N/A0.002Gap UpAIMDWAinosN/A$0.11-34.3%N/A+57.1%$0.00$20,729.000.0040Positive NewsALVOWAlvotechN/A$2.61-10.0%N/A-57.6%$0.00$391.87M0.004Short Interest ↓Positive NewsGap DownACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03flatN/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.09+66.9%N/A-7.7%$0.00$35.36M0.0070Positive NewsGap DownHigh Trading VolumeBTMDWbioteN/A$0.07flatN/A-88.4%$0.00$197.19M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.09-17.9%N/A-92.6%$0.00N/A0.008Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aardvark Therapeutics Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEXXW) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LEXXW Stock Free LEXXW Stock Alerts